In all the analyzed cancer types, the presence of at least one activated oncogene of the studied KRAS/TP53/MYC trio was sufficient to significantly increase the expression of the signature (p < 0.05) above the control group of patients (MYC expression below the average for all samples, and the WT KRAS/TP53 status). This evidence concerns the gene TP53 and cancer.